Genomic and proteomic diagnostics for lung cancer help physicians better identify patients eligible for targeted therapy or clinical trial enrollment BOULDER, Colo. --(BUSINESS WIRE)--Jan. 18, 2022-- Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in
Approximately $16.3 million in Common Shares Sold Under At-the-market Agreement Used to Offset Prepayment of Debt Second Amendment to $30 Million Term Loan Provides Additional Financial Flexibility for Growth BOULDER, Colo. --(BUSINESS WIRE)--Jan. 4, 2022-- Biodesix, Inc.